Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standardized Cat Allergen Extract + Standardized Dust Mite Allergen-Massachusetts General Hospital is a combination of biological allergen extracts used as a bronchoprovocation challenge agent in clinical research. Developed for use in physiological studies at Massachusetts General Hospital, this combination is administered via inhalation to patients with mild allergic asthma to induce a controlled asthmatic response. The mechanism involves the cross-linking of allergen-specific IgE antibodies bound to high-affinity IgE receptors (FcεRI) on the surface of mast cells and basophils in the pulmonary mucosa. This activation triggers the release of inflammatory mediators such as histamine and leukotrienes, leading to airway smooth muscle contraction (bronchoconstriction). This controlled induction of an asthma attack allows researchers to evaluate pulmonary blood flow redistribution and gas exchange impairment using advanced imaging techniques like Positron Emission Tomography (PET) and Computed Tomography (CT).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Standardized Cat Allergen Extract + Standardized Dust Mite Allergen-Massachusetts General Hospital.